Categories: News

Financière de Tubize – 2025 half-year financial report

Half-year financial report 2025
Regulated information 2 August 2025

The board of directors of Financière de Tubize has established the 2025 half-year report. This report is available on the website www.financiere-tubize.be.

  • Profit for the first half of 2025: € 95.6 million (€ 92.9 million in 2024, + 2.8%),
  • Dividend received from UCB: € 98.1 million (€ 1.39 per share, an increase of 2.2% compared to the previous year),
  • 2024 Dividend paid to Financière de Tubize’s shareholders in 2025 of € 46.3 million (€ 1.04 per share, an increase of 7.22% compared to the previous year),
  • Acquisition, in 2025, of 24,487 UCB shares, for a total amount of € 4.37 million, at an average price of € 178.3. Our stake in UCB has increased from 36.27% on 31 December 2024 to 36,28% on 30 June 2025,
  • Decrease of outstanding bank borrowings from € 41.3 million at 31 December 2024 to € nil at 30 June 2025.

Staff

Share
Published by
Staff
4 months ago

Recent Posts

MENU – ORDER AI Announces Global Expansion with New Multilingual Capabilities, Supporting WHO Guidance on Dietary Needs for GLP-1 Users

New multilingual capabilities expand access to real-time GLP-1 dining guidance as WHO highlights the importance…

58 minutes ago

AMEEREX Signs MOU to Acquire 45.6 million-Ounce Silver-Gold Project in Nevada, Expanding Its North American Precious-Metals Portfolio

ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation…

4 hours ago

Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting

SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…

10 hours ago

Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition

– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…

10 hours ago

Io Therapeutics presents today at the American Society for Hematology Annual Meeting, preclinical studies demonstrating combination treatment with BCMA CAR-T cells plus the company’s RXR agonist compound IRX4204 has synergistic efficacy against human multiple myeloma

SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…

10 hours ago

Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026

Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…

10 hours ago